I-MAB Biopharma Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 2021-05-20 06:00
I-Mab Added to MSCI China Index 2021-05-13 20:00
I-Mab Announces Upcoming Participation at May Conferences 2021-04-29 20:00
I-Mab Filed 2020 Annual Report on Form 20-F 2021-04-28 20:00
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis 2021-04-26 19:00
I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021 2021-03-03 21:00
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency 2021-02-25 21:00
I-Mab Announces Upcoming Participation at March Conferences 2021-02-24 21:00
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors 2021-02-10 21:00
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced 2021-02-09 21:00
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab 2021-02-06 06:27
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S. 2021-02-05 21:00
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China 2021-02-04 21:00
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer 2021-01-26 05:05
I-Mab Announces Upcoming Participation at January Conferences 2020-12-23 21:00
I-Mab Added to Nasdaq Biotechnology Index 2020-12-14 21:00
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China 2020-12-04 21:00
I-Mab Files Shelf Registration Statement for PIPE Investors 2020-12-02 05:23
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board 2020-12-01 21:00
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020 2020-11-11 21:00
1 4 5 6 7 8 9